($TEVA) was accelerating the uptrend but since some days it has come back on its path inside a bullish flag. It is important to note that next week earnings will be released so high volatility should be expected. Masch is about to turn on bullish mode RSI is quite down and vortex is neutral. I might expect that some investors will get long before the earnings...
As showed in the picture trend is accelerating as a sign of streght for TEVA. After some consolidation pauses we have a situation where RSI in pointing up, MACD non really clear as we have had a lateral movement, volatility stop positive. Red trendline is showing the acceleration. TP around 27 first and 30 dollars after. Despite some up and down of nasdaq, Teva...
Disclaimer, TEVA is in a very bad financial position, with dwindling cashflows and large debt. Buffet has always been the king of "value investing", hence why a position in Teva isn't surprising from him - it's most likely that he sees the company as severely undervalued and is entering into stages of repair. Buffet's new position in Teva was widely publicised...
After a couple of years where price has persistently followed the downtrend, last week Teva broke up such dynamic hreshold. Price has confirmed such trendline with a hammer 3 days ago at 17.04 dollars. Moreover we have the cross on the daily pattern between MA 50 and MA 200 turning to bullish set-up. Q1 earnings has been released beating expectations. SAR is...
TEVA usually has HUGE move on its earning release day, which is 5/2. Here we got an bullish bat pattern but it's still way too far from the entry, while with regard to the potential huge move, it worth noticing beforehand and if it actually got crashed all the way there, it could be a high-risk high-reward trade! To start this trade ,there are 2 conditions to...
We've been through DDD,VRX,GPRO to the recent TEVA stories to me MNK is just another. Back to the days I was a proprietary trader, MNK is one of my favorite name as if I don't know what to trade in any given day I tried to short the name. Only if we kept "it's never too low to sell" in mind that we can catch this kind of profit, otherwise we might be stopped out...
Despite the recent company's efforts to reduce its debit, from a technical point of view, I would be neutral with Teva until we will see a cross-over between slow 200d and fast 50d moving average on a daily chart pattern. For those who are aggressives MACD is still positive but keep in mind the resistence at 19.33 first and 20 after. Exhaustion gap betweeen 16 and...
TEVA was one of my favorite company to trade back to 2014-2015, and I was so bullish on the company then based on fundamental analysis~ After I stepped in the world of technical analysis and momentum trade, the story of TEVA has totally changed, too. There was a significant "island" formed by the exhaustion gap, and here comes an inside day. The short is the...
SEAS announces earnings on 11/7 before market open, with an implied volatility of 71%, which is at the upper end of its range over the previous 52 week period. The November 17th 11 short straddle is paying 1.37 at the mid with a comparable iron fly probably not paying enough to make it worthwhile (less than 1/4 the width of the longs). CTL (implied volatility of...
TEVA broke another monthly support zone during October. Next monthly support zone is near 13$ Where will TEVA's slide end?
TEVA is a horse in pain and Mylan is profiting from their pain!
Earnings COST announces earnings on Thursday after market close. With a background implied volatility of 21%, it doesn't meet my basic earnings play sniff test, but naturally that can increase running into earnings, so it may be worth keeping an eye on. Preliminarily, the Oct 20th 158/170 short strangle currently pays 2.21 at the mid with break evens around...
Teva Pharmaceuticals $TEVA has shed over 50% of its value following its $6.1B impairment charge and 75% dividend slash in its latest quarterly report. Pros: - The company continues to expect double digit sales growth from its recent Actavis acquisition from Allergan $AGN. - Teva expects over 1,500 new drugs to launch in 2017, with over 900 drugs still pending...
It's really tough for TEVA investors since 2016, everything seems so bad for this generic drugs giant. They finally got a new CEO and got good news from FDA, which enabled the stock price to bounce 20% in 2 days. Here we got this inside day after such a big movement, so the direction it broke becomes so important to the following sentiment on this name. Trading...
MYLAN is moving higher while TEVA and VRX is moving lower!
MYL is a buy here. just compare TEVA and VRX with MYL and you have it!
MYL and TEVA are under pressure again with market rally ~1.0% Only good support is for MYL at $28.75.